Time to start Buying?
Directors Buying
Cavendish Increasing their stake.
Good trading update and in profit 2006
Market cap of only 12mil approx

Really interested to see this one crop up here.

I have held for a good few years now and despite quite a lot of sales, orders and products the SP has been in a steady decline. Always thought that they would make a move north or perhaps even see a take-over due.

I hope to see them pick up a little in 2006 :-)

Think a takeover likley on this one in 2006

Just ticked up all buys today!

.

Don't miss the boat

Nice and positive this morning leedslad, lets hope that it continues north!

One invster on the other site said a NEW institution was buying in?
Looks like a BUY order in system.
We will have to see if we get some T trades through later.
:-)

Nice 70K BUY @ full ask

I held for a long time but in the end decided the management did not seem to think shareholdders were necessary...still potentally a very good company...but I shall await signs of appreciation before poping a toe in again...good luck to all

Yet more Director buying!!!

A good sign, waited to see what happened this week and held up despite low volume. Any predictions leedslad for future sp?
Also in MDW, will be topping up soon, hoped to top-up <12p but unlikely now?

looking for a steady run up to results in march.
No sp target short term. But looking to double from here at least by Jan 07. lots of good news to come next year 06
MDW my favorite stock for 06 :-)

More steady buying today

I am out, needed to top up in BPRG

Sorry guys - Have a good Xmas and a prosperous New Year

Baza

bhunt1910
Happy christmas
Good luck with BPRG.
Think you will need it. lol

bhunt
By the way whitch is your sell?

Well, I'm in now, just as Baza leaves!!

welcome on board andy
Going to be a good ride :-)

Chart looking good!!

Happy christmas all
dave

Leedslad - sorry for late reply

23/12/05 Sell ADV MED SOLUTIONS ORD GBP0.05 15000 8.65p 1,290.00

23/12/05 Buy BIOPROGRESS ORD GBP0.01 25000 56.40p 14,179.00

I dont suppose you will miss the last of the big spenders ?

Have a good Xmas all,

bhunt
Happy christmas and good luck in the new year

More steady buying today.

.

Another 100k BUY
Ticking up most days now.

Big Boy's still BUYING
L2
NOW 2v1
Tick up comming

And up we go again.
Break out before results in march?

L2 now 5v3
tick up comming

Nice istitutional BUY :-)

Interesting little company here.

2006 will be a big year for AMS, with US approval likely and more importantly, profitability.

I dipped my toes in on friday with a purchase of 110k shares, but the trade hasn't shown up for some reason.

The share has been a dull performer for many years, but the outlook suggests that that will change this year, now all the groundwork has been prepared.

I don't expect fireworks, but if all runs according to plan, we may see 15p at some point this year.

Got a few before Christmas at 9p, any reason for the fall back?

Todays results and directors buying, gives support to AMS

Nothing posted on this since December

Results today look excellent

Mkt cap after current move to 16p is 22.2m
Net cash is 4.2m
Leaving EV of 18m

Sales were 14.3m -- so co on 1.3x sales historic
42% gross margin --- would expect this to continue upwards

This is too low I think even now especially when they are looking to go into 2 new markets that offer "step change opportunities"

Note however tax returns boosted eps

Advanced Woundcare is main market -- 11.5m of sales -- in market sized at 50m so has 20% of market, Market expected to grow at rate of 20% plus . The only concern here is company sales rose only 9% in 2006. Do not know enuogh of company history -- product launches etc to know why.

This and other markets are fast growth and the company seems to be making the right moves . Technology seems to be supported by medical papers

My only concern is perhaps growth should be faster in current markets. But that can just be left as a concern if the management deliver on their "step change" targets. They have delivered so far.

Should see 20-22p as fair value before the step chage hits in then we could head to 30p say by the end of 2008

Nice to see my comment above - I guess if you have enough pokes your going to hit something

Well stock nicely retracing to 20p now and with summer lull likely should be able to increase holdings at this or slightly lower levels 30p still looks to be the target by end of 2008

Hi folks,
I started looking at this one a few months ago with a view that it should hit 30p (by dec 2007) if all goes well. I'm also looking to trade in and out to make extra bucks as the shares seem to swing quite nicely (at the moment). I was just wondering if anyone could tell me info on why the trade data timing on this stock is all a mishmash. I'd have sold out at 22.25 yesterday if I knew that several 100K sales had gone through. These were only reported hours afterwards (as buys). I only have the free trade data (at the moment) and am wondering if the trades are observable real time with Level II data. Anyone have any views? Any info is much appriciated.
D

dsknight

i think this is right -- if deals out of side reporting can be delayed -- if shares move in the meantime can also be difficult to tell buy or sell for sure. Hope this helps but do not treat as gospel

Results tomorrow should indicate that AMS is moving up and may declare a maiden dividend.

reporting in March -- still here on this one and continuing to climb nicely. Not sure why it keeps climbing in these markets but price action is strong lets hope they deliver as promised

Excellent products ,health sector, NHS supplier, possible takeover target,what more could you ask for, onwards to 35p.

nice results. Likely to sit around here then up to 40p by this time next year

Another one that's doing well currently. J D Slater and family have been steadily increasing their holding over the past few months, to just over 5%

SP holding up well in spite of 20 million+ sold this morning?

MDW the next one to rise like this. imho

Following yesterdays RNS confirming successful re-classification of their wound product in the US there is talk that they may now become a bid target for their competitor Johnson and Johnson. See Shares mag page 10.

RNS Number : 9428A
Advanced Medical Solutions Grp PLC
16 October 2009



For immediate release
16 October 2009

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Initial LiquiBand product introduced to US market

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that LiquiBand topical skin adhesive, the initial product for which the Group received regulatory clearance in February, has been introduced to the US market by MedLogic, its wound closure and sealants division. Further LiquiBand products are under review by the FDA.

LiquiBand, the leading topical skin adhesive in the UK accident and emergency market received 510(k) clearance from the US Food & Drug Administration (FDA) earlier this year, and is indicated for use on trauma induced lacerations, minor wounds and laparoscopic skin incisions.

The product line consisting of LiquiBand and LiquiBand Flow Control was unveiled at the American College of Emergency Physicians in Boston, 5-8 October and is being displayed at the American Academy of Pediatrics National Conference and Exposition in Washington DC, 17-20 October .

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

"We are thrilled to bring this exciting technology to clinicians and patients in the United States. LiquiBand has been sold successfully for many years in Europe and has enabled MedLogic to establish a leadership position in the use of tissue adhesives for wound closure.

"The products shown at the Emergency Physicians meeting and at the Pediatrics Conference will be commercially available in November via multiple distribution partners and further products will follow to provide a comprehensive suite of products to allow us to compete strongly in the US topical tissue adhesives market currently estimated at around $200m."

This is very good news for AMS, should push the sp up when the sales potential is realised.

Halifax - I don't know much about them (yet) will try and do a bit of research over the weekend.

skinny read RNS dated 8th september 2009 (interim results), reliable company been around since 1991, possible takeover target.... Smith&Nephew?

I have been with ams for a long time

Market is waiting for liquiband 501 approval. There was initial chatter that we would see same in October but November seems more likely.Investec and Nomura have very recently raised their forecast for the year.
All we wait for is news and if is as expected and hoped for we should see mid 30's behind us.

Smith and Nephew takes over us firm, possibly shines the light on AMS

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091111:RnsK3308C
.

Pre close statement today was liked by the market, although Ams disapointed in 2009
the potential is there to make 2010 a very good year.

another good day for advanced medical as someone with deep pockets made large purchases.

The new year continues to bring buyers. It could be that one large holder has been selling a few million but strong buying interest has been shown and the price has been on the move. the house broker has moved from beieng the seller at 33 p to the buyer at 33.50p.
We still await news from the usa, it is expected,(has been for a few months) and could be very bullish.

Continued buying has raised price for past 4 days,May need to take breath now,

Just to keep up to date

Finals due 9th March and expected to be better than was suggested at 1/2 way (see recent update statement) expecting news from usa ,but this has been expected for past 4months. Report also due from KC.
Today tip sheet(I do not know which) made them a buy and I also understand that Shares mag has also given them a buy call(I have not read this , as I am too tight to buy mag) plus 8pc this morning, is a big rise,but house broker, who has recently been on the offer has now gone so with potential 'overhang' sold rise could be genuine.

RNS possible offer from Consort.

Halifax
I will be very surprised if Consort end up buying Ams, I believe that this might bring some others to the party. Kimberley Clark is one. I do hope that this is not sold cheap.

stable yes looking at Consort's financials AMS is quite large for them to swallow although they did takeover Medical House late last year,not sure there is much synergy either.

ams finals look good, promise of 1st divi next year is in the hope of attracting institution interest.
No news re the 'bid' nor anything re kc trial results
still have to wait, if not before, hope for more info at agm.
also good report on current year trading

Todays agm statement looks bullish

Bring to the top monthly although i do seem to be the only one interested.

Bring to the top

And another high or breakout.

and another

repeat in error

I am sure there are a few dormant followers of advanced medical. Just to remind you that 1/2 year figures due Wednesday.Today's activity suggests that many want to be long before the results. The talk from management re the future trading for the year is the key to continuing upside.

Results this morning,show continuing growth.
How long before serious large company decides to take this in house?
I do not want this to happen short term as more growth to be had.

another high today finished plus 3 but was plus 5 at one time.

another up day as bid finished another 2p higher . Price has now more than doubled in past year.
Todays volume over 15 mill as some big players switching about.

small rise this am
plus1p
first added to this thread 28th Oct 2009 , price was 29p.
Last time any one else added to thread 26th Feb was 33.50
now 60 bid
I do hope that many have been in for the ride , as I expect it may well go higher, although at a slower pace as price gets closer to true value.

plus 3 p today another high, 66 bid 68 offered, I am away after tomorrow so someone else may well keep you all up to date.

doom , doom, its down 2 p today, no news,its the end of the world,and I will continue to hold.

Nobody else seems to be interested, I may be lonely but AMS continues to shine.
71.5 bid today on high volume.I do not like those that forecast market prices in the near future, but my worry is that one of the big medical houses will come along offering the money before the market realises just what this company is worth.
Why should I worry, I seem to be the only one here.

You are not alone, I'm completely with you having held shares for a few months now after a bid for the company was rejected and a higher bid did not materialise but the potential prospects were there for the company to get recognition by the City - perhaps that is beginning to happen now as I cannot see any substantial news at present to send the price on an upward spiral but long may it continue

mogkins

sorry to not to have noticed your comment before today.
I am sure that there are more than we two here but most are very bashful.
with 19 mill share trade over the past few days against an normal 2/300 k per day I am awaiting news. Some old hands are suspecting an agreed bid, I do not know other than we should be seeing an flag soon as the volume trade against the 145 mill issued must call for somebody to admit there holdings have changed.
The house broker kept away as the price jumped last week, now he is on the fringe.
Interesting times, but must stop guessing

This morning we have ourselves a breakout to a new high by the looks of it.



Recent article at proactiveinvestors.com:

Thursday, October 21, 2010

Advanced Medical Solutions sets its sights on the US
by Ian Lyall

WHAT do silver and super-glue have in common?

No idea? Well, the answer is they are the cornerstones of growth for wound-care company Advanced Medical Solutions (LON:AMS).

Silver is the infection retarding agent the company uses in the SilverCel range of dressings, while it also produces and sells super-glue. But not the type you might use to fix broken crockery.

Instead it is the sort of adhesive that instantly knits cuts back together and is marketed as LiquiBand.

But lets back up a little and find out exactly what AMS does.

Its in the market for advanced wound-care so not the bog-standard bandages and plasters you might find in the first aid kit.

Mainly its products are used for chronic wounds, which might have become infected and require a special dressing.

Its range divides into two categories - foams and fibres - which are sold through a network of major suppliers.

However it also has a budget brand which it distributes through private label partners and markets direct to the NHS. Well hear more about this later.

AMS has a small bite of the advanced wound-care market, which is conservatively estimated to be worth US$3.6 billion and which is currently dominated by a handful of bigger players.

It means the group sits under the radar of industry giants such as Smith & Nephew, Systagenix and ConvaTec, which allows it to nibble away at the trios slice of the cake.

The intellectual property that makes its dressings stand out in the marketplace is protected by around 70 separate patents, while the group is able to refresh the offering thanks to a keen focus on research and development.

The recent interim results, meanwhile, show the group is expanding at quite a rate of knots.

Revenues advanced by 47 per cent year-on-year to 14.5 million in the six months to June 30, or 25 per cent if the contribution of Corpura, the recently acquired foams business, is excluded.

Pre-exceptional profits grew 136 per cent to 2.1 million, while AMS generated 1.4 million of cash in the period.

And unlike many of the small and growing firms in the healthcare sector it is even pledging to pay a dividend.

The plan is to hand over 10 per cent of post tax earnings initially and then progressively grow the payout after that.

We are still very much a capital growth stock, says Dr Don Evans, chief executive.

But we do believe paying a dividend is a good discipline.

We have a very good institutional, private client and retail investor base. And even the institutions think paying a dividend is a good thing. It shows we have grown up.

Investec predicts pre-tax profits this year will hit 5.1 million this year and advance to 6.3 million in 2011.

Over the past five years it has built a 20 per cent market share in silver products, sold through Systagenix and other partners, and AMS wants to build on this number two position.

We can continue to grow share, says Evans.

Meanwhile, the acquisition of the outstanding 50.6 per cent stake in Dutch company Corpura a year ago gives it a very strong position in the market for foam dressings and a platform on which to challenge the opposition. The integration has gone very well, Evans confirms.

He holds out high hopes for LiquiBand, the super-glue, whose launch in the US could transform the companys sales and earnings profile.

It is up against Dermabond, made by a J&J company, which accounts for 90 per cent of all glues sold.

Evans says the group will go in with a faster setting, slightly cheaper product.

The revenue split with partners Cardinal Healthcare and McKesson provides the sales staff and the respective companies with a very good incentive to promote LiquiBand to hospitals and doctors offices.

The hope is to build an around 20 per cent share of the 155 million-a-year glues market, establishing the same sort of base it has created for other products.

We have been beavering away in the UK and Europe with LiquiBand, Evans says. "But we clearly want to get into the US."

We have taken the past three years to work through the regulatory process, which has been quite tortuous. But we got there. And we are taking two products in the US market.

If we can do a good job with our products we can really penetrate the market.

Another growth channel is the budget range ActivHeal - which plays directly to cost-constrained healthcare providers such as NHS trusts.

The products do the job technically of their big branded equivalents, but offer a big saving typically 40 per cent, says Evans.

So we can go to an NHS trust and they are spending a certain amount of their budget on advanced wound care. So for routine wounds, straightforward wounds we can offer theme a range that does the job and saves them a chunk of money.

Then if it is a difficult wound, an infected wound they can then afford the higher value products.

That message is resonating very well at the moment because of the pressure on the NHS. The problem is theres not central decision-making so you have to do it trust by trust.

It is an incremental build. That business was up 20 per cent in the first half. But we are only in half the NHS trusts at the minute.

Recently the group has moved into one single facility at Winsford in the north west, which has the potential to treble the firms capacity giving a measure of Evans ambition.

The chief executive also believes he can deliver operational benefits from the new site that ought to drop to the bottom line. And with 24m off- balance sheet tax losses AMS is not expecting to pay tax for a few years yet.

The capital spending programme, the payment of a dividend and expenditure on R&D still leaves the company with enough cash to fund bolt-one acquisitions.

However, if Evans and his team want to do something more ambitious they will have to return to the market for additional funding, the chief executive admits.

We have got options. But we have enough to drive the organic business, he adds.

But we are mindful of the opportunities. We have a strong organic story, we dont need to do M& but it is the classic case that if we see something that is a good strategic fit and accelerates growth, we will do it.



AMS At a Glance

TICKER LON:AMS

Market Cap: 100 million

Sector: Healthcare (advanced wound-care)

Employs 240 people in Winsford, Plymouth and the Netherlands

Latest results: H1 2010 pre-tax profits of 2.1 million, up 136 per cent

juzzle
Good article 3 weeks old.
What caused todays rise after period of calm?????

Very good results and all looking good for the future (even a divi)

to the top

1st half figures due next week, recent news from company shows their intentions as to taking company forward. Be dissapointed if figures next week do not show continuing profits as per expectations at least

Stable - I'm sure you are aware , I posted this on the SUN thread yesterday.

RNS Number : 3798N

Advanced Medical Solutions Grp PLC

01 September 2011

For immediate release: 1 September 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Development and Pre-Supply Agreement signed with Surgical Innovations Group plc

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has signed a Development and Pre-Supply Agreement ("the Agreement") with Surgical Innovations Group plc ("Surgical Innovations") (AIM: SUN), for the development and supply of a novel device for internal application of adhesives and sealants.

Under the terms of the Agreement, Surgical Innovations will develop and retain the intellectual property rights for a unique applicator to deliver accurately, individual drops of adhesive or sealant internally within the body, accessed via a minimally invasive surgical port site. In return for the exclusive rights to this applicator for the internal application of adhesives and sealants, AMS has agreed to purchase all of its requirements for the approved new applicator from Surgical Innovations for a period of ten years.

The development of the internal applicator is a key step in extending the Company's expertise in adhesives and sealants from purely topical applications to also addressing clinical needs inside the body. AMS has previously highlighted that the first target internal application would be the hernia mesh fixation market which is currently served by sutures, staples and tacks. This new internal applicator, together with the Company's adhesives, will allow AMS to address this important market with reduced surgical complications.

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS said:

"This agreement combines our formulation and regulatory expertise with Surgical Innovations' applicator design and manufacturing expertise to introduce a new product to a global market for internal sealants that is now in excess of US$600 million. As we have previously indicated, an integral part of our tissue sealant and adhesives R&D is focused on moving our product range more towards the Operating Room, including internal applications. In this regard, we are optimistic that our partnership with Surgical Innovations will give us a market leading product, targeting the hernia mesh fixation market, which should be available for launch in 2013."

Graham Bowland, Chief Executive Office of Surgical Innovations added:

"Our agreement with AMS affirms SI's reputation in delivering leading design solutions to OEM customers. The applicator device for AMS is a natural extension to our existing minimally invasive surgical product portfolio and we have already commenced on the design work on a fully disposable device. As part of the agreement SI will retain the full intellectual property rights to the applicator device and will also manufacture it on behalf of AMS."

skinny
Thks, I had already seen it. I think this continues to show that Ams have the mind set to develop the company as it surely leads in time for a take over.

Half Yearly Report.

Business Highlights:

LiquiBand achieves 5% volume share in the US in only its second year of sales

Sales of ActivHeal into the NHS up 64% compared to the same period last year

Foam strategy delivering strong growth of 25% on the first half of 2010

Silver alginate growth continues to outstrip the wider market

New facility already delivering operational efficiencies and margin improvements

Financial Highlights:

Group revenue up 12% to 16.3 million (2010 H1: 14.5 million)

at constant currency1 revenue increased 14%

Profit from operations (pre-exceptional items2) up 25% to 2.6 million (2010 H1: 2.1 million)

profit from operations (post exceptional items2) up 80% to 2.6 million (2010 H1: 1.5 million)

Operating margin (pre-exceptional items2) up 160 basis points to 16.1% (2010 H1: 14.5%)

operating margin (post-exceptional items2) up 610 basis points to 16.1% (2010 H1: 10.0%)
Basic earnings per share (pre-exceptional items2) up 21% to 1.72p (2010 H1: 1.42p)

basic earnings per share (post exceptional items2) up 74% to 1.72p (2010 H1: 0.99p)

Net funds3 after payment of maiden dividend were 3.6 million (2010 H1: net debt 0.3 million)

Interim dividend of 0.145p per share to be paid

RNS Number : 2417T

Advanced Medical Solutions Grp PLC

02 December 2011

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN) IS restricted and is NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

Strictly Embargoed until 07.00 2 December 2011

Advanced Medical Solutions Group plc ("AMS", the "Company" or the "Group")

Placing of 47,236,112 new Ordinary Shares in AMS at a price of 72 pence per share to raise approximately GBP34.0 million in connection with the proposed acquisition of RESORBA Wundversorgung GmbH & co. KG

The Board of AMS (AIM: AMS), the global medical technology company, is pleased to announce today the proposed acquisition of RESORBA, a long established wound care and wound closure business headquartered in Germany for a total cash consideration of EUR63.8 million (approximately GBP55 million) on a debt-free, cash-free basis to be paid, in full, on completion. To fund the acquisition, the Board of AMS also announces today a non pre-emptive institutional placing (the "Placing") of 47,236,112 new Ordinary Shares in AMS (the "Placing Shares") at a price of 72 pence per Placing Share (the "Placing Price"), to raise approximately GBP34.0 million (GBP30.5 million net of acquisition and placing expenses), together with a EUR25.0 million term loan facility.


-- The acquisition of RESORBA fulfils all of AMS's strategic
acquisition criteria and provides a number of commercial
synergy opportunities as it:
-- Broadens the Group's technology portfolio in both wound
care and wound closure;
-- Provides direct sales capability into the operating
room in Germany, Czech Republic and Russia;
-- Provides significant cross-selling opportunities and
product development potential;
-- Provides access to a new market - oral surgery;
-- Leverages AMS's global distribution network and regulatory
expertise to bring existing RESORBA products to new
markets; and
-- Provides development opportunities in the short, medium
and long term
-- RESORBA is well known to AMS as it currently distributes
its LiquiBand(R) wound closure product and has done for
more than eight years
-- Acquisition is expected to be earnings per share enhancing
in the twelve months ending 31 December 2012(1)
-- Senior management of RESORBA will be joining the Enlarged
Group and investing a material proportion of their net
proceeds from the Acquisition in AMS shares
-- Significant shareholder support for the Placing

(1) This statement is not intended, nor is to be construed as a profit forecast or to be interpreted to mean that earnings per AMS Share for the current or future financial years, or those of the Enlarged Group, will necessarily match or exceed the historical earnings per AMS Share.

Commenting on the Acquisition, Chris Meredith, Chief Executive Officer of AMS said:

"Part of our core growth strategy has been to examine potential acquisition opportunities that strengthen our business with complementary technologies and greater market access, specifically in relation to the operating room segment of our global business. It is rare to find a business that fits our criteria as well as RESORBA does. We have known RESORBA for a number of years as a result of our LiquiBand(R) relationship, and I am confident that the enlarged AMS Group will benefit from a wide range of commercial opportunities that will enable us to continue the strong progress made in recent years."

The Placing is conditional, inter alia, on Shareholder approval of the Special Resolution at the General Meeting. It is expected that the Company will post a Circular to all AMS Shareholders today with details of the Placing, Acquisition, the New Debt Facility and giving notice of the General Meeting, to be held at 11.00 a.m. on 19 December 2011 at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP. A copy of this Announcement and the Circular will be available on the Company's website, www.admedsol.com.

A bit more volume would be nice.

skinny
I think anything over 1 mill is big for ams, recent vloume on downside was one reason for not getting worried as it was very low.
It will be interesting in the middle of this month if they give an update prior to end of year, where will end 2011?

Yes I guess that comparatively speaking, the volume is well above average - I can't lay my hands on it atm, but I've had a sell note on this in the last week - more excellent coverage! :-)

Skinny
re yesterdays trading, I wonder what was the reason for the afternoon volume, either good lunches in london, or was it U.S. buying interest.I do not want a takeover in the near future as I feel all is in place for another 100 pc rise within 24 months, but, I cannot believe a large US company is not watching and knowing the short sighted Uk financial wonders they will take a nice profit if forthcoming,

re your sale note, I saw one about 10 days ago that forecast value at70p and then share magasine talked also about 70p, I wonder what they are saying this week

Now there's a bit more volume.

Standard Life < 8%

Octopus Investments > 4%

Skinny
Now u have your volume, looks like house broker has taken up the offering.
Standard dropping 500k may well be taking a profit on recent 72p purchase. They last bought at 95p,. I did read/hear somewhere that they have a limit on the amount that they will hold in any one company. Notice Octopus purchase dated last Friday so that cannot be the 72 placing as that is not yet confirmed until after the vote

nice couple of days, but must go through 95 which seems current resistance.
We might have to wait for next months results

Notice of Preliminary Results


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its preliminary results for the year ended 31 December 2011 on Wednesday 7 March 2012.

A briefing for analysts will be held at 10.30am on the day of the results at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP.

Final Results.

Financial Highlights:

• Revenue up 8% to £34.4 million (2010: £31.9 million) at actual currency and 9% at constant currency¹

• Operating margin (pre-exceptional items²) up 190 basis points to 18.6% (2010: 16.7%)

○ Operating margin (post-exceptional items²) down 20 basis points to 13.4% (2010: 13.6%)

• Operating profit (pre-exceptional items²) up 20% to £6.4 million (2010: £5.3 million)

• Operating profit (post-exceptional items²) up 6% to £4.6 million (2010: £4.3 million)

• Basic earnings per share (pre-exceptional items²) up 11% to 4.26p (2010: 3.83p)

• Basic earnings per share (post-exceptional items²) decreased 2% to 3.10p (2010: 3.17p)

• Cash inflow from operating activities (pre-exceptional items²) of £5.5 million (2010: £8.1 million)

• Cash inflow from operating activities (post-exceptional items²) of £4.9 million (2010: £7.1 million)

• Following the acquisition of RESORBA, net debt³ was £13.4 million at 31 December 2011 (2010: net funds £3.9 million)

• Proposed final dividend of 0.305p per share, making a total dividend for the year of 0.45p per share (2010: 0.38p), an increase of 18%

Business Highlights:

• Foam revenues up 49%, driven by successful new product developments and including a customer product launch

• Foam revenues up 49%, driven by successful new product developments and including a customer product launch

• Silver alginate revenues up 5% excluding de-stocking by a major partner (down 2% including de-stocking)

• LiquiBand® revenues in Europe and the UK up 13%, maintaining our significant market positions in these geographies

• End-user sales of LiquiBand® US have increased over threefold in 2011 compared with 2010

• Successful €63.8 million acquisition in December of RESORBA, a German woundcare and wound closure business, financed by new debt and equity

• New Winsford site delivers efficiency and margin gains in its first year

TANKS - i don't know this company at all, but clearly they have pooed in their nest very badly, and on that basis alone i would not be at all tempted

Cynic
Cannot see where the drop has come from other than 1)longs at 72 wanting out with mm not giving support
2 the annual shorting , again with noq resistance from the mm
No real volume and no notice from major holders.
At recent results there were no surprises but some were expecting more.
There is a meeting of company and analysts soon

no idea ... only even looked because tanks asked me to and to comment

Annual General Meeting and Update on Trading

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today.

Dr. Don Evans, Non-Executive Chairman of the Group, will make the following statement regarding current trading.

"I am pleased to report that the good start to the year, as highlighted in the 2011 Preliminary Results announcement on 7 March 2012, is continuing.

We continue to make good progress in the US market with our LiquiBand® range of products, with end-user sales increasing and further market share gains. We expect to see the impact of this progress in our ex-factory sales during the second half and we anticipate good growth for the full year. In relation to LiquiBand Flex®, we are well advanced with signing up and training distributors and are currently going through key evaluations which should be finalised by the end of the summer.

Our integration of RESORBA® is progressing to plan. We are advancing through the programme set out at the beginning of the year and we have now completed the first NHS tender for RESORBA®'s range of products, in line with our stated strategy. We expect the outcome of this first tender toward the end of the year. As a consequence of the RESORBA® acquisition, more of our Group revenues are now Euro denominated. The Group has hedged to protect profitability and, although underlying sales remain healthy, the consequent weakening of the currency could affect our headline revenue number on translation into sterling.

Elsewhere in the Group, our ActivHeal® range continues to perform well and the de-stocking effect that we experienced with one of our partners for silver alginate is now behind us. In our foam business, the targeted H2 launch of trilaminate foam dressings remains on track. However, as discussed in our Preliminary Results, 2012 foam revenues are expected to be impacted by the non-repetition of a large, roll-stock launch order in 2011, combined with our continuing strategy of focusing on higher margin business.

The effect of the expected reduction in foam revenues, together with the likely Euro impact, is that we anticipate full year Group revenues will be below expectations but with a negligible effect on profitability.

In conclusion, whilst global economic conditions remain challenging, the Board is pleased to confirm that we expect profitability for the full year 2012 to be in line with current market forecasts. The long term prospects for the Group remain excellent and we look forward to the coming months with confidence."

- ends -

First impressions look impressive with todays results, now we wait and see what the market thinks.

A buy rec in this weeks IC . shares look cheap on a discount-to-sector forward PE ratio of 14 times. Buy. Im not invested here.

Canaccord Genuity Initiates/Starts Buy TP 93p

Gone long here on AMS. Been waiting for this for a while. Now bouncing off support on gap after last results. Got plenty of broker support and outlook was pretty bullish. Worth a look.

Looks cheap forward P/E of just over
12 going into 2013.

Advanced Medical Solutions Group PLC

FORECASTS 2012 2013
Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Arden Partners
15-10-12 BUY 12.80 5.28 0.54 14.50 5.84 0.63
Peel Hunt
12-10-12 BUY 12.32 5.03 0.50 13.06 5.34 0.54
FinnCap
12-10-12 HOLD 12.10 5.70 0.50 14.00 6.90 0.50
Shore Capital
05-10-12 HOLD 12.10 5.10 0.60 14.80 5.90 0.70
Investec Securities
05-10-12 BUY 12.80 5.20 0.50 14.80 6.00 0.60
N+1 Brewin
04-10-12 HOLD 11.90 4.80 0.50 13.10 5.20 0.60
N+1 Singer
25-09-12 BUY 12.30 5.10 0.60 14.40 5.90 0.60
Canaccord Genuity Ltd
20-09-12 BUY 12.43 5.01 0.50 14.12 5.23 0.50
Nomura Code
13-09-12 BUY 12.80 5.32 0.51 14.40 5.69 0.57
Seymour Pierce
02-07-12 BUY 12.30 5.10 14.20 5.50
Numis Securities Ltd
22-06-12 BUY 12.90 5.45 0.54 15.20 6.42 0.65

2012 2013
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)
Consensus 12.43 5.19 0.52 14.13 5.81 0.58
1 Month Change -0.00 0.08 -0.01 -0.10 0.07 -0.02
3 Month Change -0.02 0.08 -0.00 -0.07 0.08 -0.03


GROWTH
2011 (A) 2012 (E) 2013 (E)
Norm. EPS 10.79% 24.48% 11.92%
DPS % -0.19% 10.30%

INVESTMENT RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £7.78m £15.54m £17.21m
EBIT £6.40m £12.45m £14.44m
Dividend Yield 0.73% 0.73% 0.80%
Dividend Cover 7.95x 9.91x 10.06x
PER 17.26x 13.86x 12.39x
PEG 1.60f 0.57f 1.04f
Net Asset Value PS 5.97p 36.15p 41.26p

As per above.....

Trading Update

Hmm, sp taken a hefty knock, not sure that it is entirely justified but there are no prisoners taken in this sector.

positive rns yesterday, see what trading update end june brings

Interim results for the six months ended 30 June 2015.

Advanced Medical Solutions is highly rated and deservedly so: great results!

New research note at http://tinyurl.com/nmr95ut

An epic fortnight for results and updates from AIM, in which Advanced Medical Solutions is also featured. See more at http://tinyurl.com/ovjm7se